PMID: 8581375Oct 1, 1995Paper

T cell activation and cytokine production in anti-CD3 bispecific antibody therapy

Journal of Hematotherapy
R Belani, G J Weiner

Abstract

The 38C13 murine lymphoma model was used to examine the role T cell activation plays in anti-CD3-based bispecific antibody therapy by comparing two bispecific antibody preparations that vary in their ability to activate T cells. Prior studies demonstrated that lower dose bispecific IgG (BsIgG) induced nonspecific T cell activation in vitro and in vivo, whereas bispecific F(ab')2 [bsF(ab')2] did not. BsIgG was more effective than bsF(ab')2 at prolonging survival of tumor-bearing mice. BsF(ab')2 was effective at prolonging survival when used along with IL-2. When used at a lower dose, the antitumor effect of both preparations was specific in that it was limited to cells bearing the target antigen. In contrast, larger doses of bsIgG, but not bsF(ab')2, resulted in regression of antigen-negative tumor, and so had therapeutic effects that were nonspecific. Serum from mice treated with larger dose bsIgG contained IFN-gamma that inhibited the growth of tumor cells in vitro. We conclude that two distinct mechanisms of action are playing a role in the observed antitumor effects. BsF(ab')2 and lower dose bsIgG inhibit tumor growth by retargeting T cells. Higher dose bsIgG also results in nonspecific T cell activation and systemic cytokin...Continue Reading

References

Jul 1, 1977·European Journal of Immunology·Y Bergman, J Haimovich
Oct 1, 1991·European Journal of Immunology·G JungW Wilmanns
Feb 15, 1989·International Journal of Cancer. Journal International Du Cancer·J van DijkR L Bolhuis
Jul 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·G D BeunA M Eggermont

❮ Previous
Next ❯

Citations

Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Jul 5, 2005·Expert Opinion on Investigational Drugs·D L DrakemanP K Wallace
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·S RiedleM Zöller

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.